Aptevo Therapeutics Files 8-K on Security Holder Vote

TL;DR

APVO filed an 8-K for a shareholder vote - check for details on what they're voting on.

AI Summary

Aptevo Therapeutics Inc. filed an 8-K on June 10, 2024, reporting on a matter submitted to a vote of its security holders as of June 7, 2024. The filing details the company's principal executive offices located at 2401 4th Avenue, Suite 1050, Seattle, Washington.

Why It Matters

This filing indicates a significant corporate action or decision requiring shareholder approval, which could impact the company's future direction and stock performance.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes can introduce uncertainty or signal significant corporate changes that may affect the company's valuation.

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• June 07, 2024 (date) — Earliest event reported
• June 10, 2024 (date) — Date of report
• 2401 4th Avenue Suite 1050 (location) — Principal Executive Offices
• Seattle, Washington (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar

Filing Documents

• apvo-20240607.htm (8-K) — 57KB
• 0000950170-24-071338.txt ( ) — 172KB
• apvo-20240607.xsd (EX-101.SCH) — 25KB
• apvo-20240607_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 7, 2024, Aptevo Therapeutics Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), at which a quorum was present. Stockholders considered four proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 23, 2024 (the "Proxy Statement"). The final voting results with respect to each of the proposals acted upon at the 2024 Annual Meeting are set forth below. Proposal 1: Election of Directors The following two nominees, each of whom were named in the Proxy Statement, were elected to serve on the Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, based on the following votes: FOR WITHHELD BROKER NON-VOTES Daniel J. Abdun-Nabi 470,470 333,623 704,366 Grady Grant, III 470,517 333,576 704,366 Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm for 2024 The appointment of Moss Adams LLP to serve as the Company's independent registered public accounting firm for the year ending December 31, 2024 was approved based on the following votes: FOR AGAINST ABSTAIN 1,271,108 232,874 4,477 Proposal 3: Approval of the Company's Second Amended and Restated 2018 Stock Incentive Plan The Aptevo Therapeutics Inc. Second Amended and Restated 2018 Stock Incentive Plan was approved based on the following votes: FOR AGAINST ABSTAIN BROKER NON-VOTES 442,849 355,401 5,843 704,366 Proposal 4: Approval, on a non-binding advisory basis, the compensation of the Company's named executive officer compensation as disclosed in the Proxy Statement. The non-binding advisory proposal was approved based on the following votes: FOR AGAINST ABSTAIN BROKER NON-VOT

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: June 10, 2024 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR